Taken together, these findings suggest that the function of the two CDK9 isoforms is likely to be at least partially distinct, although further studies are required to produce definitive evidence [26] and importantly in the cancer context, including in AML. This evidence concerns the gene CDK9 and acute myeloid leukemia.